TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
complete
Official procurement procedure

BSVI (BaseSpace Variant Interpreter)

IT services: consulting
software development
Internet and support
+1 more
London (UKI)
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: Genomics England: "BSVI (BaseSpace Variant Interpreter)". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
Contracting AuthorityGenomics EnglandScope & CategoriesNot publishedSubmission Window
complete
No deadline published
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)Not published
Bidder Intelligence · Authority Profile: Genomics England
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for Genomics England. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
3Bids / Report
50% of reports have one bid
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate available
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 3 active published awards; 2 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityGenomics England
Procedure methodNot published
Procurement categoryNot published
Statuscomplete
Framework / DPSNot published
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published10 Nov 2022, 11:21 GMT
Last source update10 Nov 2022, 11:21 GMT
Recurring procurementNot published
ClassificationIT services: consulting, software development, Internet and support, Software package and information systems
Delivery area
London (UKI)
OCIDocds-h6vhtk-0380b5
What is being bought
Software as a service including development
What changed
From the official release history
  1. Status changed to complete
    10 Nov 2022, 11:21 GMT
  2. Official notice release published
    10 Nov 2022, 11:21 GMT
  3. Buyer information updated
    10 Nov 2022, 11:21 GMT
Lots and requirements (1)
Published by the contracting authority
  • Lot 1 · #1
    Individual lot title not published
    cancelled
    Published valueNot published
    Software license subscription and services provided via the BSVI
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    10 Nov 2022, 11:21 GMT
  2. Award active
    Not published · Not published
  3. Contract active
    Signed 6 Nov 2022, 00:00 GMT · £747,520
Commercial outcome and competition
Awards
Illumina Cambridge Limited
Not published · Not published · active
Contracts
BSVI (BaseSpace Variant Interpreter)
£747,520 · signed 6 Nov 2022, 00:00 GMT · active
Bid statistics
bids: 1 (lot 1)
Buyer and organisations in this procedure

Genomics England

Contracting authority GB-FTS-8859
View buyer profile

  • Genomics England
    buyer

    Dawson Hall, Charterhouse Square, London, UKI, EC1M 6BQ
    supplier.engagement@genomicsengland.co.uk
    +44 2078825030

  • High Court
    reviewBody

    London

  • Illumina Cambridge Limited
    supplier

    Cambridge, UKH, CB21 6DF
Documents (0)
Official links; attachments are not copied
No data
No linked documents are published
Related procedures (0)
No data
No related procedures published
Planning and rationale
Planning budgetNot published
No-engagement rationaleNot published
Procedure rationaleUnder a contract dated 9 February 2016 between Genomic England Limited (GEL) and Illumina Cambridge Limited (“Illumina”), the parties co-developed a product for GEL being the Base Space Variant Interpreter (“BSVI”) which is not otherwise available on the market. Under the terms of that agreement Illumina retained certain intellectual property rights in the product, while the cost of the product to GEL reflected GEL’s role in co-development. It should be noted therefore that BSVI is a very bespoke product provided by Illumina to Genomics England alone and Illumina will retire the product once GEL no longer has a need for it. The original agreement expired in March 21. In November 2019 Genomics England separately signed a contract with Illumina for the provision of sequencing and related services to support the soon to be implemented NHS Genomic Medicine Service (“GMS”) (“Sequencing Contract”) which is due to expire on 31 October 2025. In March 2021 Genomics England varied the Sequencing Contract to include the provision of the BSVI product as part of its scope for a period of 18 months. Genomics England has on 6 November 2022 entered into a further amendment to the Sequencing Contract under which BSVI will be provided until expiry of the contract or until such earlier time as GEL confirms its long term strategy for securing decision support for cancer for the GMS with its partner, NHS England and procures an alternative or updated solution to meet the new strategy requirements. We expect this to be for a period between 12 and 24 months. Genomics England takes the view that Regulation 72 (1) (b) applies to the variation to the Sequencing Contract because additional services from Illumina have become necessary but were not included in the original procurement of this contract but a change of contractor cannot be made at this time due to the bespoke technical specification of the product and it would also cause significant duplication of cost for GEL. The value of the variation is under 50% of the value of the Sequencing Contract. NHS England has confirmed that a functioning decision support system for cancer is essential to the success of the GMS for cancer and no hiatus in these services is possible. Genomics England has very specific requirements for decision support as any product needs to fit in with its internal National Genomics Informatics System pipeline and no off the shelf product is available or viable without significant development. Given the background to BSVI development, an immediate termination would not only have led to a hiatus in service but would cause substantial inconvenience and duplication of costs should a new decision support provider be brought in. A new procurement will require preparation and proper planning to meet the future objectives of the service yet to be agreed with NHS England. In the event that this were to be considered a new contract award, we consider that Regulation 32 (2) (b) of the Public Contract Regulations 2015 would apply in any event for the same reasons. There is no other product available in the market to meet the immediate need and requirements and Illumina holds the IP rights to the product. Any supplier would need to substantially develop its standard product to fit Genomics England’s needs. This would include customising release cycles to fit the needs of the NHS. BSVI is a very specific product developed for a single customer. For this reason, there is no genuine competition for the BSVI product on the market today and time will be required for GEL to plan for its ultimate replacement.